Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
Leucine-rich, glioma inactivated 1, also known as LGI1, is a protein which in humans is encoded by the LGI1gene. It may be a metastasis suppressor.
Function
The leucine-rich glioma inactivated -1 gene is rearranged as a result of translocations in glioblastoma cell lines. The protein contains a hydrophobic segment representing a putative transmembrane domain with the amino terminus located outside the cell. It also contains leucine-rich repeats with conserved cysteine-rich flanking sequences. This gene is predominantly expressed in neural tissues and its expression is reduced in low grade brain tumors and significantly reduced or absent in malignant gliomas.
Clinical significance
Since its earliest discovery, the LGI1 gene has been implicated in the control of cancer metastasis and in a predisposition to epilepsy. Following genetic linkage studies placing the hereditary form of autosomal dominant partial epilepsy with auditory features (ADPEAF) on chromosome region 10q24 mutation analysis of affected members in these families demonstrated LGI1 was a major cause of the disease.
More recently, LGI1 has been shown to be the major target of human autoantibodies which immunoprecipitate voltage-gated potassium channel complexes from mammalian brain tissue. LGI1 antibodies are found in patients with limbic encephalitis and in patients with faciobrachial dystonic seizures (FBDS). FBDS are a recently described form of epilepsy which is characterized by frequent, brief seizures which affect the arm and face. They appear to be preferentially responsive to immunotherapy over anti-epileptic drugs.
Wilson MH, Puranam RS, Ottman R, Gilliam C, Limbird LE, George AL, McNamara JO (December 1998). "Evaluation of the alpha(2A)-adrenergic receptor gene in a heritable form of temporal lobe epilepsy". Neurology. 51 (6): 1730–1. doi:10.1212/wnl.51.6.1730. PMID9855534. S2CID85601127.
Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, S Zagami A, Bleasel A, Somerville ER, Smith SM, Vincent A (May 2011). "Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis". Annals of Neurology. 69 (5): 892–900. doi:10.1002/ana.22307. PMID21416487. S2CID13775077.
Gu W, Brodtkorb E, Steinlein OK (September 2002). "LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures". Annals of Neurology. 52 (3): 364–7. doi:10.1002/ana.10280. PMID12205652. S2CID2957451.
Pizzuti A, Flex E, Di Bonaventura C, Dottorini T, Egeo G, Manfredi M, Dallapiccola B, Giallonardo AT (March 2003). "Epilepsy with auditory features: a LGI1 gene mutation suggests a loss-of-function mechanism". Annals of Neurology. 53 (3): 396–9. doi:10.1002/ana.10492. PMID12601709. S2CID26216565.
Fertig E, Lincoln A, Martinuzzi A, Mattson RH, Hisama FM (May 2003). "Novel LGI1 mutation in a family with autosomal dominant partial epilepsy with auditory features". Neurology. 60 (10): 1687–90. doi:10.1212/01.wnl.0000063324.39980.4a. PMID12771268. S2CID41281964.
Kunapuli P, Chitta KS, Cowell JK (June 2003). "Suppression of the cell proliferation and invasion phenotypes in glioma cells by the LGI1 gene". Oncogene. 22 (26): 3985–91. doi:10.1038/sj.onc.1206584. PMID12821932. S2CID6720407.
Bisulli F, Tinuper P, Scudellaro E, Naldi I, Bagattin A, Avoni P, Michelucci R, Nobile C (September 2004). "A de novo LGI1 mutation in sporadic partial epilepsy with auditory features". Annals of Neurology. 56 (3): 455–6. doi:10.1002/ana.20218. PMID15349881. S2CID26953058.